Journal of Pharmacology and Pharmacotherapeutics

RESEARCH PAPER
Year
: 2017  |  Volume : 8  |  Issue : 3  |  Page : 106--111

Efficacy and tolerability of olmesartan, telmisartan, and losartan in patients of stage I hypertension: A randomized, open-label study


Mrunalini Kalikar, Kundan S Nivangune, Ganesh N Dakhale, Chaitali S Bajait, Smita D Sontakke, Vijay M Motghare, Ritu Budania 
 Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India

Correspondence Address:
Mrunalini Kalikar
39, Chirantan, Shivaji Nagar, Nagpur - 440 010, Maharashtra
India

Objectives: To compare the efficacy and tolerability of losartan, telmisartan, and olmesartan as antihypertensive agents and evaluate and compare their effects on lipid profile and blood glucose. Materials and Methods: This was a randomized, open-label, parallel-group, comparative study conducted in sixty patients of Stage I hypertension. The eligible patients were randomly allocated into three treatment groups: (1) Tablet olmesartan (20 mg), (2) Tablet telmisartan (40 mg), and (3) Tablet losartan (50 mg). Blood pressure (BP) was assessed at an interval of 2 weeks for 3 months. Fasting blood glucose (FBG) and lipid profile were estimated at baseline and then at 12 weeks. Results: Olmesartan and telmisartan were more efficacious than losartan in reducing diastolic BP (DBP). There was a statistically significant decrease in mean blood glucose level (P < 0.02) after 12 weeks of treatment in telmisartan group when compared to baseline. Serum total cholesterol, triglycerides, and low-density lipoproteins decreased significantly after 12-week treatment with olmesartan and telmisartan. Conclusions: The most efficacious drug in reducing BP is Olmesartan whereas telmisartan and losartan show equal efficacy. Telmisartan shows the most favorable effects on FBG and lipid profile.


How to cite this article:
Kalikar M, Nivangune KS, Dakhale GN, Bajait CS, Sontakke SD, Motghare VM, Budania R. Efficacy and tolerability of olmesartan, telmisartan, and losartan in patients of stage I hypertension: A randomized, open-label study.J Pharmacol Pharmacother 2017;8:106-111


How to cite this URL:
Kalikar M, Nivangune KS, Dakhale GN, Bajait CS, Sontakke SD, Motghare VM, Budania R. Efficacy and tolerability of olmesartan, telmisartan, and losartan in patients of stage I hypertension: A randomized, open-label study. J Pharmacol Pharmacother [serial online] 2017 [cited 2018 Sep 26 ];8:106-111
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2017;volume=8;issue=3;spage=106;epage=111;aulast=Kalikar;type=0